  Monitoring treatment response after chemotherapy of gadolinium- ( Gd)- negative gliomas is challenging as conventional MRI often indicates no radiological changes. We hypothesize that Sixty-one patients harboring Gd-negative WHO grade II or III glioma receiving alkylating agents ( temozolomide or CCNU/procarbacine) were included. All patients underwent MRI and None None